Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK NICE Says Yes To Vizimpro & Libtayo But Rejects Tagrisso

Executive Summary

Pfizer and AstraZeneca were seeking National Health Service funding for the same indication for their respective lung cancer drugs. With "responsible pricing" after an initial rejection, Pfizer prevailed.

You may also be interested in...



AstraZeneca To Fight NICE Knockback For Tagrisso In England

Following NICE’s rejection last week for Tagrisso, AstraZeneca argues that the health technology appraisal body was wrong not to take the company’s real-world data into account when considering whether the lung cancer drug should be granted “end of life” status.

Sanofi's Libtayo Lands In EU With Skin Cancer Nod

Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.

Tagrisso Funding Journey Shows UK’s Revamped Cancer Drugs Fund Is No Soft Touch

AstraZeneca’s Tagrisso is the first product accepted for use on the National Health Service through the reformed Cancer Drugs Fund, but it took two tries to persuade HTA body NICE it should be funded at all. NICE examined Merck Sharp & Dohme’s Keytruda and it’s not impressed. The Pink Sheet takes a closer look at the new dynamics illustrated by these lung cancer treatments’ review.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel